NURIX
Live / Applied — Statement of use — registration review complete (as of 19 Aug 2026)
What this means for you
Not registered yet, but its 06 Sept 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98738213
- Mark type
- Design + words
- Filed
- 06 Sept 2024
- Published for opposition
- 15 Apr 2025
- Attorney of record
- Gazal Pour-Moezzi
Goods and services
- Class 005 — Pharmaceuticals: Biological and pharmaceutical preparations for the treatment of cancer and immune-related disorders
Owner
- Nurix Therapeutics, Inc., Brisbane, CA, US
- Nurix Therapeutics, Inc., San Francisco, CA, US
Prior registrations
Prosecution history
- 08 Sept 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 08 Sept 2026 — REGISTERED-PRINCIPAL REGISTER
- 19 Aug 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 19 Aug 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 18 Aug 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 22 Jul 2026 — USE AMENDMENT FILED
- 22 Jul 2026 — TEAS STATEMENT OF USE RECEIVED
- 30 Jun 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 Jun 2026 — SOU EXTENSION 2 GRANTED
- 08 Jun 2026 — SOU EXTENSION 2 FILED
- 09 Jun 2026 — SOU TEAS EXTENSION RECEIVED
- 05 Jun 2026 — DIVISIONAL PROCESSING COMPLETE
- 25 Nov 2025 — DIVISIONAL REQUEST RECEIVED
- 27 May 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 22 Apr 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL